NRx Pharmaceuticals

NRx Receives Initial Report of Patient Safety and Survival from Right to Try Use of ZYESAMI During Omicron Surge

RADNOR, PA — NRx Pharmaceuticals (NASDAQ: NRXP has received a first safety report from a Southwestern hospital where physicians have administered ZYESAMI® (Aviptadil) to patients with COVID-19 respiratory failure.

NRx Receives Initial Report of Patient Safety and Survival from Right to Try Use of ZYESAMI During Omicron Surge Read More
Immunome

Immunome Provides Update on Investigational New Drug Application for IMM-BCP-01 for the Treatment of COVID-19

EXTON, PA — Immunome, Inc. (Nasdaq: IMNM) announced a recent update regarding its Investigational New Drug (IND) submission for IMM-BCP-01, a three-antibody cocktail, for the treatment of SARS-CoV-2 (COVID-19).

Immunome Provides Update on Investigational New Drug Application for IMM-BCP-01 for the Treatment of COVID-19 Read More